Crossmark

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

Crossref DOI link: https://doi.org/10.1038/s41467-022-30569-0

Published Online: 2022-05-31

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Jieqiong

Wang, Ying

Tian, Zhenluan

Lin, Ying

Li, Hengyu https://orcid.org/0000-0001-8354-2224
Zhu, Zhaowen

Liu, Qiang https://orcid.org/0000-0002-5451-4862
Su, Shicheng https://orcid.org/0000-0003-2280-3587
Zeng, Yinduo

Jia, Weijuan

Yang, Yaping

Xu, Shengqiang

Yao, Herui https://orcid.org/0000-0001-5520-6469
Jiang, Wen https://orcid.org/0000-0001-9154-633X
Song, Erwei https://orcid.org/0000-0002-5400-9049
License Information

Text and Data Mining valid from 2022-05-31

Version of Record valid from 2022-05-31
More Information

Article History

Received: 28 January 2022

Accepted: 6 May 2022

First Online: 31 May 2022

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below